Elranatamab in Relapsed/Refractory Multiple Myeloma

This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.

Trial Details

NCT ID
NCT06711705
Phase
PHASE2
Sponsor
University of California, San Diego
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Elranatamab
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742

Key Eligibility Criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Prior diagnosis of relapsed/refractory MM and have received 1 to 3 prior lines of therapy as defined by the IMWG criteria (Rajkumar et al., 2014) i…
  • Refractory is defined as having disease progression while on therapy or within 60 days of last dose in any line, regardless of response.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →